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Abstract
Background: Almost half of Diabetic Peripheral Neuropathies (DPNs) are symptom-free. Methods including
questionnaires and electrodiagnosis (EDx) can be fruitful for easy reach to early diagnosis, correct treatments of
diabetic neuropathy, and so decline of complications for instance diabetic foot ulcer and prevention of high costs.
The goal of our study was to compare effectiveness of the Michigan neuropathy screening instrument (MNSI),
United Kingdom screening test (UKST) and electrophysiological evaluation in confirming diabetic peripheral
neuropathy.
Methods: One hundred twenty five known diabetes mellitus male and female subjects older than 18 with or
without symptoms of neuropathy comprised in this research. All of them were interviewed in terms of
demographic data, lipid profile, HbA1C, duration of disease, and history of retinopathy, so examined by Michigan
neuropathy screening instrument (MNSI), United Kingdom screening test (UKST), and nerve conduction studies
(NCS). The collected data were analyzed by SPSS software 18.
Results: One hundred twenty five diabetic patients (70 female, 55 male) were recruited in this study with a mean
age of 58.7 ± 10.2, and mean duration of diabetes was 10.17 ± 6.9 years. The mean neuropathy score of MNSI and
UKST were 2.3 (1.7) and 4.16 (2.9), respectively. Each instrument detected the peripheral neuropathy in 78 (69 %)
and 91 (73 %) of patients, respectively. There was a significant relationship between number of neuropathies and
mean of diabetes duration and development of retinopathy in both questionnaire evaluations and NCS. By nerve
conduction study, neuropathy was detected in 121 (97 %) diabetic patients were reported in order 15 (12 %)
mononeuropathy (as 33 % sensory and 67 % motor neuropathy) and 106 (85 %) polyneuropathy (as 31 % motor
and 69 % sensorimotor neuropathy).
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Conclusions: As regards NCS is an objective, simple, and non-invasive tool and also can determine level of damage
and regeneration in peripheral nerves, this study suggests electrodiagnosis as a convenient option for screening,
confirming, and follow up of diabetic peripheral neuropathy.
Keywords: Diabetic peripheral neuropathy, Electrodiagnosis, Michigan neuropathy screening instrument, United
Kingdom screening test
Background
The most common complication of diabetes mellitus is
neuropathy as a consequence of chronic hyperglycemia.
Advanced glycation products, aldose reductase, protein
kinase C, polyol and some cytokines are among neuro-
toxic byproducts involved in pathophysiology of hyper-
glycemia induced diabetic peripheral neuropathy [1–7].
There is a wide spectrum of nerve involvement in dia-
betes with wide variety of manifestation from focal to
diffuse, symmetric or asymmetric and autonomic symp-
toms [8].
Diabetic peripheral neuropathy (DPN) is the most com-
mon acquired neuropathy and one of the main complica-
tions of diabetes mellitus (DM) due to high rate of its
prevalence, hospitalizations, morbidities and mortalities.
The valid prevalence is unknown through various
criteria and methods for characterizing neuropathy,
however, based on prior studies, the prevalence of
DPN approximated 10–90 % generally and 16–87 %
in Iran [9, 10].
DPN is diagnosed by symptoms and signs, but given
that almost half of DPNs are symptom-free, other
methods including questionnaires and electrodiagnosis
(EDx) can be fruitful for easy reach to early diagnosis,
correct treatments of diabetic neuropathy, and so de-
cline of complications for instance diabetic foot ulcer
and prevention of high costs [11–14].
Michigan neuropathy screening instrument (MNSI)
and United Kingdom screening test (UKST) with ques-
tions about location and severity of clinical signs and
symptoms of neuropathy are commonly used to assess
DPN [13]. based on physician’s clinical examination and
patient’s self-report.
The goal of our study was to compare effectiveness of
the Michigan neuropathy screening instrument (MNSI),
United Kingdom screening test (UKST) and electro-
physiological evaluation in confirming diabetic periph-
eral neuropathy.
Methods
This cross sectional study was performed in the Endo-
crinology and Metabolism Research Institute of Tehran
University of Medical Sciences. One hundred twenty five
known diabetes mellitus subjects confirmed by endocri-
nologists with more than 18 years of age, both male and
female with or without symptoms of neuropathy com-
prised in this research.
Patient with psychological problem, potential for per-
ipheral neuropathy consisting of hereditary sensory
neuropathy, vitamin B12 or folate deficiency, paraneo-
plastic diseases, autoimmune conditions, organs failure,
hypothyroidism prolonged phenytoin or immunosup-
pressive drugs consumption, and ethanol abuse were ex-
cluded from the study [13].
All of them were interviewed in terms of demo-
graphic data, lipid profile, HbA1C, duration of dis-
ease, and history of retinopathy, so examined by
Michigan neuropathy screening instrument (MNSI),
United Kingdom screening test (UKST), and nerve
conduction studies (NCS).
Instrument
Michigan neuropathy screening instrument (MNSI)
MNSI has two steps to assess history of neuropathic
symptoms and physical examination to evaluate the ap-
pearance and sensation of feet. An objective test with
four questions included foot skin inspection for deform-
ities, dry skin, calluses, infections, fissures, and ulcer,
ankle reflex, and vibration sensation tested by a 128 HZ
tuning fork placed over great toe. The test was com-
pleted by expert physician. A score ≥ 2 is considered ab-
normal. Abnormality in each item gets grades 0.5 to 1
and at lease more than 2 abnormal items needed to
reach the score of neuropathy [15].
United Kingdom screening test (UKST)
A simple, subjective and symptom-based instrument
which is composed of five questions about type, severity
and location of symptoms and maximum 9 scores. Its
cut-off point is ≥ 2 [16, 17].
Electrophysiological assessment
NCS is the most fruitful component of the electrodiag-
nostic evaluation, so a simple, noninvasive, objective,
and sensitive measurement which is intended as a gold
standard test for corroborating the diagnosis of periph-
eral neuropathy [18–22].
There is no general consensus for polyneuropathy criteria
in NCS in the face of multiple performed investigations
[18]. Because of DPN is length-dependent neuropathy,
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lower extremity nerves are probably involved more, we de-
signed our study accordingly [23].
NCS consists of bilateral peroneal and tibial nerves
compound muscle action potential (CMAP) and sural
nerves sensory nerve action potential (SNAP), nerve
conduction velocity (NCV), amplitude, and distal latency
performed by board-certified physiatrists and electro-
myographers via using 2-channel Oxford (Medelec-Syn-
ergy) electromyography instrument. Normal values were
considered based on valid data [24].
For peroneal nerve CMAP, recording electrode was at-
tached on extensor digitorum brevis and peroneal nerve
was stimulated distally at ankle, lateral to tibialis anterior
tendon and proximally a few centimeters distal to the
fibular head.
For tibial nerve CMAP, recording electrode was at-
tached on abductor hallucis muscle and tibial nerve was
stimulated in the popliteal fossa and proximally posterior
to the medial malleolus proximal to the flexor
retinaculum.
For sural nerve SNAP the recording electrode was at-
tached on posterior aspect of lateral malleolus and the
stimulator was positioned 14 cm proximally in the pos-
terior aspect of leg’s midline [25].
Ethical considerations
The Research Committee of Endocrinology and Metab-
olism Research Institute of Tehran University of Medical
Sciences approved the study. Ethically each patient
signed the informed consent form before participation
in the study.
Statistical analysis
To explain continuous and qualitative variables, mean
[standard deviation (SD)] and frequency (percentage)
were utilized, respectively. Continuous variables were
compared by independent sample T-test, or Mann-
Whitney U test whenever the data did not appear to
have normal distribution or when the assumption of
equal variances was violated across the study groups.
Pearson chi-square test was used to evaluate the propor-
tion of the qualitative variables between groups. In this
study, a P value <0.05 as statistically significant, in
addition, SPSS software version 18.0 was applied.
Results
One hundred twenty five diabetic patients were re-
cruited in this study. They included 70 (56 %) female
and 55 (44 %) male with a mean age of 58.7 ± 10.2, ran-
ging from 22 to 77 years of age, 17 (14 %) type 1 DM
and 108 (86 %) type 2 DM. Mean duration of diabetes
history was 10.17 ± 6.9 years. Demographic characteris-
tics of the patients are reported in Table 1.
In the neuropathy evaluation, the mean score of MNSI
and UKST were 2.3 (1.7) and 4.16 (2.9), respectively. In
accordance with specified cut-off point in MNSI and
UKST, peripheral neuropathy was detected in 78 (69 %)
and 91 (73 %) of patients, respectively.
Classification of neuropathy severity based on UKST
score as follows,
Healthy or without neuropathy (0–1): 34 (27 %), mild
(2–4): 24 (19 %), moderate (5–6): 34 (27 %) and severe
(7–9): 33 (26 %).
As reported in Table 2, there was a significant relation-
ship between number of neuropathies and mean of dia-
betes duration in both questionnaire evaluations and
NCS, however, according to HbA1C, not statistically sig-
nificant difference in MNSI.
Our results showed that hyperlipidemia (total choles-
terol > 200 or triglyceride > 150) and obesity, body mass
index (BMI) > 30 did not have significant difference with
neuropathy in both questionnaire assessments and NCS.
Twenty six subjects of retinopathy (based on positive
history of laser therapy) evaluated by MNSI, UKST and
NCS, their P-values were statistically significant (0.050
and 0.025 respectively).
Neuropathy was diagnosed based on one or more ab-
normal findings in nerve conduction study, including
distal latency, amplitude and velocity of conduction in
the tested nerve and therefore 121 (97 %) neuropathic
Table 1 Baseline and general characteristics of recruited
patients













Table 2 Relationship between neuropathy and diabetes
duration or HbA1C
Neuropathy Yes No P value
DM duration (MNSI) 11.5 ± 6.4 7.8 ± 7.2 0.003
HbA1C (MNSI) 7.9 ± 2.2 7.8 ± 2.7 0.808
DM duration (UKST) 11.2 ± 7.09 7.15 ± 5.8 0.003
HbA1C (UKST) 8.2 ± 2.3 6.8 ± 2.3 0.024
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patients were reported in order 15 (12 %) mononeuropa-
thy (as 33 % sensory and 67 % motor neuropathy) and
106 (85 %) polyneuropathy (as 31 % motor and 69 %
sensorimotor neuropathy). Frequency of neuropathy
based on involved nerves and assessment tests showed
in Tables 3 and 4, respectively.
In this study there is statistically significant agreement be-
tween electrophysiological assessment with UKST and
MNSI in diagnosis of sensory neuropathy (p < 0.001). There
is a strong correlation between the MNSI and UK total
score (Pearson’s correlation coefficient = 0.43, p < 0.001).
By considering NCS as a comparative standard in this
population of diabetic patients, the sensitivity of UKST
was 63.93 %, the specificity 50 % and the positive/nega-
tive likelihood ratios were 1.28 and 0.72. For MNSI these
were 75.21 %, 33.3 %, 1.13 and 0.74 respectively.
Discussion
Diabetic peripheral neuropathy is a prevalent problem
with secondary complications can cause different suffer-
ings such limb amputation, also may expand before diag-
nosis and being symptomatic, following from this; the
diagnosis of neuropathies is very important in suitable
time in result. Owing to absence of a thorough diagnos-
tic criteria and accurate instrument, various methods
were designed for this purpose [11, 12, 26].
Diagnosis of neuropathy founded on physical examina-
tions, questionnaires, nerve conduction studies and skin
biopsies, however, initially researchers propounded some
questionnaires in addition to physical examinations, but
the results showed they are less efficient because of be-
ing essentially subjective, time consuming and its de-
pendence on both patient and examiner, also unable to
detect all cases of neuropathy and their severities [26].
In a study [27], slowed NCV was revealed in 100 % of
lower and 48 % of upper extremities of tested diabetic
patients. In another study, asymmetric distal neuropathy
totally occurred in 84 % [28], and in some other studies
[29, 30] also showed reduced sensory and motor NCVs
in almost all participants.
Our research showed that percentage of discovered
neuropathies by mentioned questionnaires are between
69 and 73 %; however, this amount for electrophysiologic
assessment is between 85 and 97 % according to the se-
lected criteria.
Our findings, as previous studies, showed that elec-
trophysiological assessment in diabetes mellitus
achieved higher sensitivity to diagnose motor and
sensory neuropathies in comparison with screening
questionnaires [31, 32], which explainable by higher
sensitivity of electrophysiological studies in early de-
tection of subclinical neuropathies.
According to the Table 4, the most of diagnosed
neuropathies with MNSI, UKST, and NCS are related
to type 2 diabetes mellitus and the reason of high
prevalence of DPN in adult-onset diabetes can be
further damage of large fiber nerves and more ability
of these three tools for large fiber neuropathy
screening [24, 33, 34].
Conclusions
MNSI and UKST are sensitive screening instruments for
routine evaluation of diabetic patients. As regards NCS
is an objective, simple, and non-invasive tool and also
can determine level of damage and regeneration in per-
ipheral nerves, this study suggests electrodiagnosis as a
convenient option for screening, confirming, and follow
up of diabetic peripheral neuropathy. In addition, the
role of NCS in early detection of subclinical neuropa-
thies makes it a suitable test for periodic evaluation of
diabetic patients even with normal MNSI and UKST
screening studies.
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Table 3 Frequency of neuropathy based on involved nerve
Nerve Amplitude Latency NCV %
Right tibial 43.2 % 3.2 % 26.4 % 49.6 %
Left tibial 48.8 % 4.8 % 29.6 % 53.6 %
Right peroneal 68 % 35.2 % 40 % 75.2 %
Left peroneal 75.2 % 29.6 % 52 % 81.6 %
Right sural 49.6 % 17.6 % 25.6 % 52 %
Left sural 51.2 % 21.6 % 24 % 81.6 %
Table 4 Frequency of neuropathy based on assessment tests
Test Type 1 DM Type 2 DM
MNSI 16.9 % 83.1 %
UKST 15.6 % 84.4 %
EDx 14.2 % 85.8 %
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